Abstracts tagged "lupus nephritis and systemic lupus erythematosus (SLE)"

Abstract Number: 1641 • 2017 ACR/ARHP Annual Meeting
Indications for Initial Renal Biopsy in Systemic Lupus Erythematosus: A Systematic Review of the Literature
Andrew McKinnon¹, Annaliese Tisseverasinghe², Susan Barr³, Paul R. Fortin⁴, John G. Hanly⁵, Stephanie Keeling⁶ and Christine A. Peschken², ¹Internal Medicine, University of Manitoba, Winnipeg, MB, Canada, ²Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ³Medicine, University of Calgary, Calgary, AB, Canada, ⁴Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Québec, QC, Canada, ⁵Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada, ⁶Department of Medicine, University of Alberta, Division of Rheumatology, Edmonton, AB, Canada
Background/Purpose: Lupus nephritis (LN) is an important cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). An initial renal biopsy (RB) is…
Abstract Number: 2620 • 2017 ACR/ARHP Annual Meeting
The Value of Repeat Biopsy in the Management of Lupus Nephritis Flares
Javier Narváez^1,2, Milagros Ricse², Montserrat Goma³, Francesca Mitjavila⁴, Xavier Fulladosa⁵, Olga Capdevila⁴, Joan Torras⁵, Xavier Juanola^2,6, Ramon Pujol⁴ and Joan Miquel Nolla², ¹Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ²Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Pathology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Internal Medicine, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁵Nephrology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Rheumatology, University Hospital Bellvitge, Barcelona, Spain
Background/Purpose: Whether a repeat renal biopsy is helpful during lupus nephritis (LN) flares remains debatable. Our objective was to analyze the clinical utility of repeat…
Abstract Number: 2922 • 2017 ACR/ARHP Annual Meeting
Outcomes of Lupus Nephritis in Vulnerable Populations
Christine Peschken¹, Rebecca Gole², Carol A Hitchon³, David Robinson³, Ada Man⁴, Annaliese Tisseverasinghe⁴ and Hani El-Gabalawy⁴, ¹Medicine & Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, ²University of Manitoba, Winnipeg, MB, Canada, ³Arthritis Center, University of Manitoba, Winnipeg, MB, Canada, ⁴Rheumatology, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Lupus nephritis is a known predictor of mortality; we have previously shown an increased frequency of nephritis in North American Indian (NAI) and Asian…
Abstract Number: 2795 • 2016 ACR/ARHP Annual Meeting
Effect of Complete or Partial Proteinuria Recovery Compared to No Recovery at 2 Years after the Diagnosis of Lupus Nephritis on Long Term Outcomes
Jorge Medina-Rosas¹, Dafna D. Gladman², Jiandong Su³, Murray Urowitz² and Zahi Touma², ¹Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Proteinuria is the most common manifestation of lupus nephritis (LN) and it is an independent prognostic factor of long term outcomes. Recovery from…
Abstract Number: 2820 • 2016 ACR/ARHP Annual Meeting
Comprehensive Aptamer-Based Screening of 1129 Proteins Reveals Novel Urinary Biomarkers of Lupus Nephritis
Samantha Stanley¹, Huihua Ding², Claudia Pedroza³, Ramesh Saxena⁴, Michelle Petri⁵ and Chandra Mohan¹, ¹Biomedical Engineering, University of Houston, Houston, TX, ²Biomedical Engineering Department, University of Houston, Houston, TX, ³Pediatrics, University of Texas-McGovern Medical School, Houston, TX, ⁴Nephrology, University of Texas Southwestern Medical Center, Dallas, TX, ⁵Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: An aptamer-based screening assay was used to analyze the levels of 1129 different proteins in 24 human urine samples (8 active lupus nephritis (LN),…
Abstract Number: 2858 • 2016 ACR/ARHP Annual Meeting
Urinary PF4 and E-Selectin As Novel Biomarkers for Disease Activity and Renal Damage in Lupus Nephritis
Huihua Ding¹, Ling Qin¹, Samantha Stanley¹, Ramesh Saxena² and Chandra Mohan³, ¹Biomedical Engineering Department, University of Houston, Houston, TX, ²Nephrology, University of Texas Southwestern Medical Center, Dallas, TX, ³Biomedical Engineering, University of Houston, Houston, TX
Background/Purpose: Lupus nephritis (LN) is the leading cause of morbidity and mortality in systemic lupus erythematosus (SLE). The objective of this study is to validate…
Abstract Number: 2882 • 2016 ACR/ARHP Annual Meeting
CD4+ T Helper Cells and Regulatory T Cells in Active Lupus Nephritis – an Imbalance Towards a Predominant Th1 Response?
Danilo Mesquita Jr.¹, Marcello Fabiano Franco², Gianna Mastroianni Kirsztajn¹, Luciana Aparecida Reis¹, Sandro Perazzio³, Fernanda Vieira Mesquita¹, Vanessa Ferreira¹, Luis E C Andrade⁴ and Alexandre W.S. Souza⁵, ¹Internal Medicine, Universidade Federal de São Paulo, São Paulo, Brazil, ²Pathology, Universidade Federal de São Paulo, São Paulo, Brazil, ³Rheumatology Division, Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁴Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, Brazil, ⁵Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic inflammatory disease characterized by the involvement of multiple organs and systems with aberrations in T cell response,…
Abstract Number: 776 • 2016 ACR/ARHP Annual Meeting
Eurolupus and Low Steroid Regimen in Proliferative Lupus Nephritis: Retrospective Evaluation of 38 Patients in the Black Population of Martinique
Charles Cartou¹, Katlyne Polomat², Florence MOINET², Serge ARFI³, Lauren Brunier-Agot⁴, Marie Blattery⁵, Aymeric Couturier⁶, Georges JEAN BAPTISTE⁷, Michel De Bandt⁸ and Christophe Deligny⁹, ¹nephrology, Pierre Zobda Quitman Hospital, Fort de France, Martinique, ²Rheumatology and Internal Medicine, Zobda Quitman Hospital, Fort de France, Martinique, ³University Hospital, CHU Fort de France, Fort de France, Martinique, ⁴Internal medicine and rheumatology, Zobda Quitman Hospital, Fort de France, Martinique, ⁵rheumatology, Pierre Zobda Quitman hospital, Fort de France, Martinique, ⁶nephrology, Pierre Zobda Quitman hospital, Fort de France, Martinique, ⁷RHEUMATOLOGY, CHU MARTINIQUE, FWI, Fort-de-France, Martinique, ⁸CHU Fort de France, Fort de France, France, ⁹Zobda Quitman Hospital, Rheumatology and Internal Medicine, Fort de France, Martinique
Background/Purpose: There is no data on the efficacy of the EUROLUPUS regimen associated with initial low steroids daily dose in African descent patients with proliferative…
Abstract Number: 964 • 2016 ACR/ARHP Annual Meeting
Tubulointerstitial Damage Is an Independent Predictor of End Stage Renal Disease in Lupus Nephritis Patients with Mild to Moderate Renal Impairment
Bojana Jovanovic¹, Hina N. Khan¹, Wenzhu Mowrey¹, Peter M. Izmirly², Daniel Schwartz¹, Jill P. Buyon³, Chaim Putterman¹, Beatrice Goilav¹ and Anna R. Broder¹, ¹Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ²New York University School of Medicine, New York, NY, ³Medicine, New York University School of Medicine, New York, NY
Background/Purpose: Tubulointerstitial damage (TID) is considered to be a later sequela of lupus nephritis (LN). The clinical significance of TID in patients with only…
Abstract Number: 966 • 2016 ACR/ARHP Annual Meeting
Renal Activity in Lupus (RAIL) Urinary Biomarkers Predict Treatment Response
Gaurav Gulati¹, Michael Bennett², Khalid Abulaban^3,4, Qing Ma⁵, Marisa S. Klein-Gitelman⁶, Kelly A. Rouster-Stevens⁷, Christopher Haffner⁵, Kasha Wiley⁸, Stacy P. Ardoin⁹, Jun Ying¹⁰, Prasad Devarajan¹¹ and Hermine I. Brunner⁸, ¹Division of Immunology, Allergy and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH, ²Division of Nephrology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ³Department of Pediatrics, Division of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Pediatric Rheumatology, Helen DeVos Children's Hospital, Grand Rapids, MI, ⁵Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁶Div of Pediatric Rheumatology/PDD PTD, Lurie Children's Hospital of Chicago/NW University, Chicago, IL, ⁷Pediatric Rheumatology, Emory Children's Center, Atlanta, GA, ⁸Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹Pediatric & Adult Rheumatology, Ohio State University, Columbus, OH, ¹⁰Center for Biostatistical Services, University of Cincinnati College of Medicine, Cincinnati, OH, ¹¹Dept of Nephrology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH
Renal Activity In Lupus (RAIL) Urinary Biomarkers Predict Treatment Response Background/Purpose: We have previously demonstrated the strong predictive value of the Renal Activity In Lupus…
Abstract Number: 2062 • 2016 ACR/ARHP Annual Meeting
Increased Expression of Response Gene to Complement-32 in Kidney Biopsies from Patients with Lupus Nephritis
Julie Yip¹, Vinh Nguyen², Alexandru Tatomir^3,4, Armugam Mekala^4,5, Dallas Boodhou⁴, Horea Rus^3,4, Cinthia Drachenberg⁶ and Violeta Rus^5,7, ¹Rheumatology and Clinical Immunology, University of Maryland School of Medicine, Baltimore, MD, ²Medicine, University of Maryland School of Medicine, Baltimore, MD, ³Neurology, Research Service, VAMHCS, Baltimore, MD, ⁴Neurology, University of Maryland School of Medicine, Baltimore, MD, ⁵Research Service, VAMHCS, Baltimore, MD, ⁶Pathology, University of Maryland School of Medicine, Baltimore, MD, ⁷Medicine/Rheum & Clinc Immun, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: RGC (Response Gene to Complement)-32 is a cell cycle regulator widely expressed in normal tissues including brain, kidney, spleen, thymus, multiple tumors and in…
Abstract Number: 755 • 2015 ACR/ARHP Annual Meeting
Validating the RAIL Algorithm in Adult Lupus Nephritis Patients
Gaurav Gulati¹, Khalid Abulaban², Jun Ying³, Xiaolan Zhang⁴, Huijuan Song⁵, Qing Ma⁶, Christopher Haffner⁶, Kasha Wiley⁷, Michael Bennett⁸, Brad H. Rovin⁵ and Hermine I. Brunner⁹, ¹Division of Immunology, Allergy and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH, ²Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³University of Cincinnati, Cincinnati, OH, ⁴Ohio State University, Columbus, OH, ⁵Ohio State University Medical Center, Columbus, OH, ⁶Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁷Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Division of Nephrology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ⁹Pediatric Rheumatology Collaborative Study Group, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Lupus Nephritis (LN) significantly contributes to morbidity and mortality among Systemic Lupus Erythematosus (SLE) patients. We have established the Renal Activity Index for Lupus…
Abstract Number: 1071 • 2015 ACR/ARHP Annual Meeting
Single-Cell RNA Sequencing of Human Podocytes, Endothelial Cells, and Tubular Cells Identifies Markers and Gene Profiles Differentiating Class IV and Class V Renal Disease in Lupus Nephritis
Evan Der¹, Kemal Akat², Robert Clancy³, Beatrice Goilav⁴, Anna R. Broder⁵, H. Michael Belmont⁶, Peter M. Izmirly⁷, Nicole Jordan⁸, Tao Wang⁹, James Pullman¹⁰, Daniel Schwartz¹⁰, Ming Wu¹¹, Thomas Tuschl², Jill P. Buyon³ and Chaim Putterman¹², ¹Albert Einstein College of Medicine, Bronx, NY, ²Rockefeller University, New York, NY, ³Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴Division of Nephrology, Children's Hospital at Montefiore, Bronx, NY, ⁵Rheumatology-Forchheimer 701N, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, ⁶Hosp for Joint Disease, New York, NY, ⁷Rheumatology, NYU School of Medicine, New York, NY, ⁸Montefiore Medical Center, New York, NY, ⁹Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, NY, ¹⁰Pathology, Albert Einstein College of Medicine, Bronx, NY, ¹¹Pathology, New York University School of Medicine, New York, NY, ¹²Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Currently, classification and treatment decisions in lupus nephritis (LN) are largely based on renal histology. Transcriptome analysis may accurately differentiate types of renal involvement,…
Abstract Number: 1845 • 2015 ACR/ARHP Annual Meeting
HMGB1 Early Marker in Lupus Nephritis
Aisha Badawy¹, Randa Salam², Hanan Fouad³, Amira Bassam⁴ and Sahar Lashen⁵, ¹Internal medicine cairo university, professor of internal medicine and rheumatology, cairo, Egypt, ²Internal medicine cairo university, Assistant professor internal medicine, cairo, Egypt, ³medical biochemistry cairo university, Professor of medical biochemistry, cairo, Egypt, ⁴pathology Cairo university, Lecturer of Pathology Cairo university, cairo, Egypt, ⁵Internal medicine, assistant lecturer of internal medicine cairo university, cairo, Egypt
Background/Purpose: Systemic Lupus Erythematosis is a systemic autoimmune disease characterised by involvement of multiple organ systems Lupus nephritis (LN) is a severe and frequent manifestation…
Abstract Number: 1847 • 2015 ACR/ARHP Annual Meeting
Serum Ferritin and Insulin-like Growth Factor-Binding Protein 2 As Biomarkers of Clinical and Histopathological Treatment Response in Lupus Nephritis
Ioannis Parodis¹, Huihua Ding², Agneta Zickert¹, Chandra Mohan² and Iva Gunnarsson¹, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ²Biomedical Engineering, University of Houston, Houston, TX
Background/Purpose: Lupus nephritis (LN) is a severe manifestation of Systemic Lupus Erythematosus (SLE). Renal biopsy is gold standard for evaluation of renal activity and damage…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].